“The drug pricing provisions of the IRA, which was signed into law in August 2022, began to be implemented in 2023 and implementation efforts will continue over the next several years. In August 2023, the Biden Administration unveiled the first round of medicines subject to the “Medicare Drug Price Negotiation Program,” which requires manufacturers of select drugs to engage in a process with the Federal government to set new Medicare prices which would go into effect in 2026. Among the medicines included in the first round is Eliquis. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. In addition, changes to the Medicaid program or the federal 340B drug pricing program, including legal or legislative developments at the federal or state level with respect to the 340B program, could have a material impact on our business.”
All entries for: Neutral Outlook
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
Regeneron
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
“The IRA did not have a material impact on the Company’s financial statements for the three and nine months ended September 30, 2023.”
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
Regeneron
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
Regeneron
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
“Adverse Effects”: “…the recently enacted federal Inflation Reduction Act (IRA) contains provisions that could have an adverse effect on our ability to generate revenue, attain profitability, or commercialize our product candidates if approved, as the statute includes provisions intended to reduce the cost of prescription drugs under Medicare. In addition to the direct impact of the IRA on federal drug reimbursement, the statute may also lead to similar reductions in payments from private payers. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect [List of items]”
